Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Radius Health (RDUS) Trades to Session Lows
October 12, 2015 2:41 PM EDTRadius Health (Nasdaq: RDUS) is moving to session lows Monday after the company announced the... More
Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover Plays
October 12, 2015 12:06 PM EDTRadius Health (NASDAQ: RDUS) and Dyax Corp (NASDAQ: DYAX) highlighted as a potential takeover targets on... More
Radius Health (RDUS) Presents Positive Phase 3 Data from ACTIVE Trial at ASBMR Meeting
October 12, 2015 6:51 AM EDTRadius Health, Inc. (Nasdaq: RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial InVertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo. Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, along with positive pharmacokinetic data from a study evaluating the ABL... More
